Glycogen Storage Disease Type 1a (GSD-1a) Treatment and Market Landscape Report 2024 [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
Needs, Emerging Therapies, and Value & Access" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive report on Glycogen Storage Disease Type 1a (GSD-1a) offers a thorough evaluation of the disease's pathophysiology, underlining potential targets that could be influential in the development of new treatments. As the report elaborates, GSD-1a is a critical metabolic disorder that affects the body's capacity to process glycogen, which can lead to severe health complications if not managed correctly. Epidemiology Insights The study provides detailed epidemiological data to better understand the GSD-1a prevalence and its impact on affected populations in the United States and the EU5. These insights serve as an essential basis for strategic planning in healthcare resource allocation and management for this rare condition. Current Treatment Analysis With no FDA-approved therapies, the existing treatment paradigm is explored extensively within the rep
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Stifel Nicolaus from $66.00 to $69.00. They now have a "buy" rating on the stock.MarketBeat
- Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at JPMorgan Chase & Co. from $45.00 to $48.00. They now have an "overweight" rating on the stock.MarketBeat
BEAM
Earnings
- 5/7/24 - Beat
BEAM
Sec Filings
- 9/3/24 - Form 4
- 8/19/24 - Form 3
- 8/6/24 - Form 10-Q
- BEAM's page on the SEC website